Sequence-based discovery of a synthetic peptide inhibitor of caspase 6

Apoptosis

Volumn 8, Issue 4, 2003, Pages 371-376

  Nyormoi, O ^a   Wang, Z ^b   Bar Eli, M ^b  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Caspase 6; Neurodegenerative diseases; Synthetic peptide inhibitor

Indexed keywords

BENZYLOXYCARBONYLASPARTYLARGINYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLLYSYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLGLUTAMYLISOLEUCYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE INHIBITOR; SYNTHETIC PEPTIDE; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP 2ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BREAST CANCER; CANCER CELL; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ADAPTOR PROTEIN COMPLEX 2; AMINO ACID SEQUENCE; ANIMALS; CASPASE 6; CASPASE 8; CASPASE 9; CASPASES; CELL LINE, TUMOR; CYSTEINE PROTEINASE INHIBITORS; HUMANS; OLIGOPEPTIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0042668508     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024173018750     Document Type: Article

References (41)

1. Williams T, Admon A, Luscher B, Tijian R. Cloning and expression of AP-2, a cell-type specific transcription factor that activates inducible enhancer elements. Genes Dev 1988; 2: 1557-1569.
2. Moser M, Pscherer A, Roth C, et al. Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2β. Genes Dev 1997; 11: 1938-1948.
3. Oulad-Abdelghani M, Bouillet P, Chazaud C, Dolle P, Chambon P. AP-2.2: A novel AP-2-related transcription factor induced by retinoic acid during differentiation of P19 embryonal carcinoma cells. Exp Cell Res 1996; 225: 338-347.
4. Gaynor RB, Muchardt C, Xia YR, et al. Localization of the gene for the DNA-binding protein AP-2 to human chromosome 6p 22.3 pter. Genomics 1991; 10: 1100-1102.
5. Williamson JA, Bosher JM, Skinner JM, et al. Chromosomal mapping of the human and mouse homologues of two new members of the AP-2 family of transcription factors. Genomics 1996; 35: 262-264.
6. Zhao F, Satoda M, Licht JD, et al. Cloning and characterization of a novel mouse AP-2 transcription factor, AP-2delta, with unique DNA binding and transactivation properties. J Biol Chem 2002; 276: 40755-40760.
7. Schorle H, Meier P, Buchert M, Jaenisch R, Mitchell PJ. Transcription factor AP-2 essential for cranial closure and craniofacial development. Nature 1996; 381: 235-238.
8. Zhang J, Hagopian-Donaldson S, Serbedzija G, et al. Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2. Nature 1996; 381: 238-241.
9. Shen H, Wilke T, Ashique AM, et al. Chicken transcription factor AP-2: Cloning, expression and its role in outgrowth of facial prominences and limb buds. Dev Biol 1997; 188: 248-266.
10. WAF1/CIP1 expression. Nature Genetics 1997; 15: 78-81.
11. van den Oord JJ, Vandeghinste N, De Ley M, et al. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994; 145: 294-300.
12. Aggarwal BB, Singh S, LaPushin R, Totpal K. Fas antigen signals proliferation of normal human diploid fibroblast and its mechanism is different from tumor necrosis factor receptor. FEBS Lett 1995; 364: 5-8.
13. Nyormoi O, Wang Z, Doan D, Ruiz M, McConkey D, Bar-Eli M. Transcription factor AP-2α is preferentially cleaved by caspase-6, and degraded by proteasome during TNFα-induced apoprosis in breast cancer cells. Mol Cell Biol 2001; 21: 4856-4867.
14. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983; 11: 1475-1489.
15. Nyormoi O, Schneider T, Smith RG. A large scale preparative gel electrophoresis separation of alpha 1 and alpha 2 subunits of the voltage-gated Ca2+ channel channel frochannel from rabbit skeletal muscle. Electrophoresis 1994; 15: 1186-1190.
16. Nyormoi O. Proteolytic activity in amyotrophic lateral sclerosis IgG preparations. Ann Neurol 1996; 40: 701-706.
17. Cohen GM. Caspases: The executioners of apoptosis. Biochem J 1997; 326: 1-16.
18. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999; 68: 383-424.
19. Peter ME, Heufelder AE, Hengartner MO. Advances in apoptosis research. Proc Natl Acad Sci USA 1997; 94: 12736-12737.
20. Roth KA, D'Sa C. Apoptosis and brain development. Ment Retard Dev Disabil Res Rev 2001; 7: 261-266.
21. Lacelle C, Xu S, Wang E. Identification of high caspase-3 mRNA expression as a unique signature profile for extremely old individuals. Mech Aging Dev 2002; 123: 1133-1144.
22. Pollack M, Phaneuf S, Dirks A, Leeuwenburgh C. The role of apoptosis in the normal aging brain, skeletal muscle, and heart. Ann NY Acad Sci 2000; 959: 93-107.
23. Springer JE, Nottingham SA, McEwen ML, Azbill RD, Jin Y. Caspase-3 apoptotic signaling following injury to the central nervous system. Clin Chem Lab Med 2001; 39: 299-307.
24. Kim M, Lee HS, LaForet G, et al. Mutant huntingtin expression in clonal striatal cells: Dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci 1999; 19: 964-973.
25. Rideout HJ, Stefanis L. Caspase inhibition: A potential therapeutic strategy in neurological diseases. Histol Histopathol 2001; 16: 895-908.
26. Hand CK, Rouleau GA. Familial amyotrophic lateral sclerosis. Muscle Nerve 2002; 25: 135-159.
27. Vukosavic S, Stefanis L, Jackson-Lewis V, et al. Delaying caspase activation by Bcl-2: A clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2000; 20: 9119-9125.
28. Ecder T, Melnikov VY, Stanley M, et al. Caspases, Bcl-2 proteins and apoptosis in autosomal-dominant polycystic kidney disease. Kidney Int 2002; 61: 1220-1230.
29. Garden GA, Budd SL, Tsai E, et al. Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci 2002; 22: 4015-4024.
30. Holcik M, Gibson H, Korneluk RG. XIAP: Apoptotic brake and promising therapeutic target. Apoptosis 2001; 6: 253-261.
31. Van Den Brande JM, Peppelenbosch MP, Van Deventer SJ. Treating Crohn's disease by inducing T lymphocyte apoptosis. Ann NY Acad Sci 2002; 973: 166-180.
32. Wellington CL, Hayden MR. Caspases and neurodegeneration: On the cutting edge of new therapeutic approaches. Clin Genet 2000; 57: 1-10.
33. Guttenplan N, Lee C, Frishman WH. Inhibition of myocardial apoptosis as a therapeutic target in cardiovascular disease prevention: Focus on caspase inhibition. Heart Dis 2001; 3: 313-318.
34. Salgado J, Garcia-Saez AJ, Malet G, Mingarro I, Perez-Paya E. Peptides in apoptosis research. J Pept Sci 2002; 8: 543-560.
35. Hirata H, Takahashi A, Kobayashi S, et al. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med 1998; 187: 587-600.
36. Zhou Q, Snipas S, Orth K, Muzio M, Dixit VM, Slvesen GS. Target protease specificity of viral serpin CRM A: Analysis of five caspases. J Biol Biochem 1997; 272: 7797-7800.
37. Hay BA, Wolff T, Rubin GM. Expression of baculovirus p35 prevents cell death in Drosophila. Development 1994; 120: 2121-2129.
38. Yang YL, Li XM. The IAP family: Endogenous caspase inhibitors with multiple biological activities. Cell Res 2000; 10: 169-177.
39. Liu W, Staecker H, Stupak H, Malgrange B, Lefebvre P, Van De Water TR. Caspase inhibitors prevent cisplatin-induced apoptosis of auditory sensory cells. Nueroreport 1998; 9: 2609-2614.
40. Talanian RV, Quinlan C, Trautz S, et al. Substrate specificities of caspase family proteases. J Biol Chem 1997; 272: 9677-9682.
41. Thornberry NA, Rano TA, Peterson EP, et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. Biol Chem 1997; 272: 17907-17911.